In summary, the cumulative evidence suggests that various sources of Gal1 can effectively impede cytotoxic T cells, which serve as pivotal tumour-killing effectors, thereby establishing an immune-privileged environment within tumours. This evidence concerns the gene LGALS1 and neoplasm.